HK1023143A1 - Intracellular production of hepatitis c e2 truncated polypeptid - Google Patents

Intracellular production of hepatitis c e2 truncated polypeptid

Info

Publication number
HK1023143A1
HK1023143A1 HK00101959.7A HK00101959A HK1023143A1 HK 1023143 A1 HK1023143 A1 HK 1023143A1 HK 00101959 A HK00101959 A HK 00101959A HK 1023143 A1 HK1023143 A1 HK 1023143A1
Authority
HK
Hong Kong
Prior art keywords
truncated
polypeptid
hepatitis
intracellular production
polypeptides
Prior art date
Application number
HK00101959.7A
Other languages
English (en)
Inventor
Michael Hougton
Qui-Lim Choo
Sergio Abrignani
David Chien
Mark Selby
Edward Glazer
Original Assignee
Novartis Vaccines & Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostics Inc filed Critical Novartis Vaccines & Diagnostics Inc
Publication of HK1023143A1 publication Critical patent/HK1023143A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/923—Cell culture

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK00101959.7A 1997-05-06 2000-03-30 Intracellular production of hepatitis c e2 truncated polypeptid HK1023143A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4567597P 1997-05-06 1997-05-06
PCT/US1998/009097 WO1998050556A2 (en) 1997-05-06 1998-05-06 Intracellular production of hepatitis c e1 and e2 truncated polypeptides

Publications (1)

Publication Number Publication Date
HK1023143A1 true HK1023143A1 (en) 2000-09-01

Family

ID=21939272

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00101959.7A HK1023143A1 (en) 1997-05-06 2000-03-30 Intracellular production of hepatitis c e2 truncated polypeptid

Country Status (10)

Country Link
US (2) US6521423B1 (xx)
EP (1) EP0980434B1 (xx)
JP (3) JP4458556B2 (xx)
AT (1) ATE437951T1 (xx)
AU (1) AU7471698A (xx)
CA (1) CA2288374A1 (xx)
DE (1) DE69841015D1 (xx)
ES (1) ES2328536T3 (xx)
HK (1) HK1023143A1 (xx)
WO (1) WO1998050556A2 (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999066033A1 (en) * 1998-06-18 1999-12-23 The Government Of The United States Of America, Represented By The Secretary, Department Of Healtha Nd Human Services Surface targeted expression of a modified hepatitis c virus envelope protein
US6432411B1 (en) * 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection
AU1236801A (en) 1999-10-27 2001-05-08 Chiron Corporation Activation of hcv-specific t cells
DK1233782T3 (da) * 1999-12-01 2009-02-09 Novartis Vaccines & Diagnostic Fremkaldelse af HCV-specifikke antistoffer
US7094882B2 (en) 2000-04-21 2006-08-22 Yeda Research And Development Co. Ltd. Growth factor which acts through erb b-4 rtk
CU23244A1 (es) * 2001-07-16 2007-10-17 Ct Ingenieria Genetica Biotech Formulacion vacunal potenciada por la combinacion de un adn con un antigeno
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
US8029803B2 (en) * 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8025873B2 (en) * 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
RU2353399C2 (ru) * 2003-01-17 2009-04-27 Этлон Медикал, Инк. Способ удаления вирусов из крови посредством лектин-аффинного гемодиализа
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
US8007805B2 (en) * 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
EP1602664A1 (en) * 2004-03-08 2005-12-07 Innogenetics N.V. HCV E1 comprising specific disulfide bridges
EP1574517A1 (en) * 2004-03-09 2005-09-14 Innogenetics N.V. HCV E1 comprising specific disulfide bridges
EP1783218A4 (en) * 2004-06-25 2009-02-18 Advanced Life Science Inst Inc HCV RNA WITH NEW SEQUENCE
AU2005295317B2 (en) * 2004-10-18 2011-10-13 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
ZA200804078B (en) * 2005-10-13 2009-09-30 Virexx Medical Corp Chimeric hepatitis C virus antigens for eliciting an immune response
US8815253B2 (en) 2007-12-07 2014-08-26 Novartis Ag Compositions for inducing immune responses
JP2012503011A (ja) 2008-09-19 2012-02-02 グローブイミューン，インコーポレイテッド 慢性ｃ型肝炎ウイルス感染の免疫療法
US20210145963A9 (en) 2013-05-15 2021-05-20 The Governors Of The University Of Alberta E1e2 hcv vaccines and methods of use
US10300131B2 (en) 2015-07-07 2019-05-28 The Governors Of The University Of Alberta Hepatitis C virus immunogenic compositions and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1049686C (zh) 1987-11-18 2000-02-23 希龙股份有限公司 非ａ和非ｂ肝炎病毒的诊断及疫苗
KR0185373B1 (ko) 1989-03-17 1999-05-01 로버트 피. 블랙버언 Hcv 폴리단백질에서 유래되는 hcv 아미노산 서열 부분을 포함하는 폴리펩티드 및 그 사용
DK0398748T3 (da) 1989-05-18 2002-03-18 Chiron Corp NANBV-diagnostika: polynukleotider anvendelige til screening for hepatitis C virus
JPH06504431A (ja) 1990-11-08 1994-05-26 カイロン　コーポレイション Ｃ型肝炎ウイルスアシアロ糖タンパク質
US6274148B1 (en) * 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
DK0721505T4 (da) 1994-07-29 2006-08-14 Innogenetics Nv Rensede hepatitis C-virus-kappeproteiner til diagnostisk og terapeutisk anvendelse
WO1996004301A2 (en) 1994-07-29 1996-02-15 Chiron Corporation Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same
ES2316920T3 (es) * 1994-07-29 2009-04-16 Novartis Vaccines And Diagnostics, Inc. Popipeptido truncado e2 de hepatitis c y procedimientos para obtener el mismo.

Also Published As

Publication number Publication date
DE69841015D1 (de) 2009-09-10
WO1998050556A2 (en) 1998-11-12
CA2288374A1 (en) 1998-11-12
JP2009232863A (ja) 2009-10-15
EP0980434B1 (en) 2009-07-29
WO1998050556A3 (en) 1999-02-11
ES2328536T3 (es) 2009-11-13
US20040001854A1 (en) 2004-01-01
JP4458556B2 (ja) 2010-04-28
EP0980434A1 (en) 2000-02-23
US7429385B2 (en) 2008-09-30
US6521423B1 (en) 2003-02-18
ATE437951T1 (de) 2009-08-15
AU7471698A (en) 1998-11-27
JP2002504810A (ja) 2002-02-12
JP2008195722A (ja) 2008-08-28

Similar Documents

Publication Publication Date Title
HK1023143A1 (en) Intracellular production of hepatitis c e2 truncated polypeptid
AU1750297A (en) Humanized green fluorescent protein genes and methods
AR018023A1 (es) Procedimiento para la fabricacion de polipeptidos con glicosilacion apropiada
WO2000053761A3 (en) Human cytokine as ligand of the zalpha receptor and uses thereof
PT989999E (pt) Composicao anti-tumoral a base de polipeptido imunogenico de localizacao celular modificada
IL130190A0 (en) Methods and compositions for polypeptide engineering
DE60132699D1 (de) Nukleinsäuren und polypeptide, die sich auf b7 beziehen und ihre verwendungen zur immunmodulierung
IL127874A0 (en) Truncated soluble tumor necrosis factor type-I and type-II receptors
IL144018A0 (en) Truncated glial cell line-derived neurotrophic factor
TR200000175T2 (tr) Endogenik gen aktivasyonu ile eritropoietinin hazırlanması.
CA2155185A1 (en) Totally synthetic affinity reagents
AU6733487A (en) Mammalian interleukin-4
EP0833912A4 (en) NEW TRANSFORMING GROWTH FACTOR TYPE CYTOKINE TGF-BETA
SG65593A1 (en) Totally synthetic affinity reagents
CA2160131A1 (en) New Bacillus Thuringiensis Strains and Their Insecticidal Proteins
DE69637856D1 (en) Interleukin-19.
CA2097698A1 (en) Human dopamine d4 receptor and its uses
MXPA03000227A (es) Compuestos novedosos.
IL117459A (en) Dna encoding human papillomavirus type 18
DE59610251D1 (de) Konjugat, umfassend einen wirkstoff, ein polypeptid und einen polyether
IL129139A0 (en) Vertebrate smoothened proteins
DE69634757D1 (de) Vektor zur expression von n-terminal verlängerten proteinen in hefezellen
EP1331265A3 (en) density enhanced protein tyrosine phosphatases
ATE403735T1 (de) Episomaler vektor und dessen verwendung
WO2004089973A3 (en) Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160506